ÖZET

Amaç:

Aksiller lenf nodülü metastazının (ALNM) tanı anındaki durumu, meme kanseri olan hastaların genel ve hastalıksız sağkalımı için en önemli prognostik faktörlerden biri olarak kabul edilmiştir. ALNM riski taşıyan meme kanseri hastalarının belirlenmesi, tedavi planı için önemlidir. Bu çalışmamızın amacı meme kanserinde aksiller lenf nodu tutulumunu etkileyen faktörleri gereksiz diseksiyon yapılan hasta grubunu belirlemek idi.

Yöntemler:

Meme kanseri nedeni ile cerrahi tedavi uygulanan 131 meme kanseri hastanın immünohistokimyasal ve patolojik özellikleri retrospektif olarak incelenerek kaydedildi.

Bulgular:

ALNM hastaların %60’ında (n=79) saptanmıştır. Univariate analizde histolojik grade, tümör boyutu, lenfovasküler invazyon, perinöral invazyon, HER2 pozitifliği ve geniş intraduktal bileşen ALNM için yüksek riskli bulundu. Multivariate analizde, artmış tümör boyutu (OR: 0,2, p<0,030) ve lenfovasküler invazyon varlığı (OR: 0,2, p<0,001), pozitif ALNM için bağımsız faktörler olarak bulundu.

Sonuç:

Çalışmamızda lenfovasküler invazyon varlığı, artmış tümör boyutu, aksiller lenf nodu tutulumu için bağımsız prediktif faktörler olarak bulundu. Univariate analizde histolojik grade, tümör boyutu, lenfovasküler invazyon, perinöral invazyon, HER2 pozitifliği ve geniş intraduktal bileşen ALNM için yüksek riskli bulundu. Bu faktörleri taşıyan hastalar, lenf nodu tutulumu için daha yüksek risk grubuna dahil edilebilir, ancak aksiller lenf nodu disseksiyonu için karar vermede yardımcı olabilecek faktörleri tanımlamak için daha fazla veri gerekmektedir.

References

1Fisher B, Slack NH. Number of lymph nodes examined and prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131:79-88.

2Berg JW, Robbins GF. Factors influencing short and longterm survival of breast cancer patients. Surg Gynecol Obstet 1966;122:1311-6.

3Saez RA, Clark GM, Mc Guire WL. Prognostic factors in breast cancer. Semin Surg Oncol 1989;5:99-102.

4Fisher B, Boyer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update. Cancer 1983;52:1551-7.

5Nemeto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: Results of a national survery by the American Colloge of Surgeons. Cancer 1980;45:2917-24.

6Ernst MF, Voogd AC, Balder W, Klinkenbijl JH, Roukema JA. Early and late morbidity associated with axillary levels I-III dissection in breast cancer. J Surg Oncol 2002;79:151-5.

7Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American college of surgeons. Cancer 1980;45:2917-24.

8Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status. Ann Surg 1980;192:148-51.

9Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patient. JAMA 1996;276:1818-22.

10Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.

11Joensuu H, Toikanen S, Klemi PJ. DNA index and S phase fraction and their combinations as prognostic factors in operable ductal breast carcinoma. Cancer 1990;66:331-40.

12Crowe JR, JP Gordon NH, Shenk RR, Zolliger RM, Brumberg DJ, Shuck JM. Primary tumor size. Relevance to Breast Cancer Survival. Arch Surg 1992;127:910-5.

13Robbins GF, Leis HP Jr, Hutter Rup. A rational approach to and result of women with breast carcinoma. J Breast 1997;3:9-13.

14Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.

15Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997;38:366-8.

16Wong JS, Recht A, Beard CJ, et al. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys 1997;9:119-32.

17Tavanssol F. Pathology of the breast. 2nd Ed. Stamford, Connecticut: Appleton Lange 1999;52-3.

18Giri DD, Dundas SAC, Nothingam JF, Underwood JCE. Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: An immunohistological study. Histopathology 1989;574-84.

19Knight WA, Livingstone RB, Gregory EJ, Mc Guire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Research 1977;37:4669-71.

20Clark GM, Mc Guire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988;15:20-5.

21Slamon DJ, Godolphin W, James CA, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.

22Paik S, Byyant J, Park C, et al. Erb B-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Cancer Inst 1998;90:1361-70.

23Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.

24Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.

25Pinder SE, Ellis IO, Galea M, O’Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-7.

26Mansour EG, Rravdin PM, Dressler L. Prognostic factors in early breast cancer. Cancer 1994;74:381-400.

27Topuzlu C. Meme Koruyucu Cerrahi. Sayek ‹, editör. Temel Cerrahi. 3. Bask›. Ankara: Güneş Kitabevi; 2004. p: 959-65.

28Karanlık H, Özmen V, Asoğlu O, et al. Meme kanseri cerrahi tedavisinin uzun dönem sonuçları. Meme Sağlığı Dergisi 2006;2:89-95.

29Azambuja E, Cardoso F, de Castro G, et al. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13.

30Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential, Lancet Oncol 2010;11:174-83.

31Harden SP, Neal AJ, Al-Nasiri N, Ashley S, Querci della Rovere G. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. Breast 2001;10:155-9.

Meme Kanserinde Aksilla Metastazini Etkileyen Prediktif Faktörler

ÖZET

References